How do you review prices for multiple drugs, across multiple markets, instantly? PharmaFootpath is a business intelligence tool for pharmaceutical companies. Bringing together product information, prices, clinical trials, tenders, parallel imports, and more, into a single easy-to-use site. Make smarter decisions. Find new opportunities. Win more business.
External link for Pharma Footpath
London, GB
Want to talk about how comparator sourcing companies, parallel traders, and other international trading companies use our data to find new opportunities? Meet us in #expopharm !
Pharma Footpath will be attending ExpoPharm 2024 in Munich! If you'd like to say hello, and even have a quick look over the way he help clients use data to grow their businesses, send us a message and book a slot!
Italian Parallel Import data is more challenging to gather than many other markets, but it's an important market to track. Some insights... 👇 - 1,482 parallel trade licenses have been granted to bring stock into Italy, though 248 are no longer commercialised. - 17 different companies hold these licenses. GMM Farma being the biggest with 269 licenses approved, including 24 granted in 2024. - Bayer's oral contraceptive Yasmin is the most contested parallel import product, with 12 different companies holding PI licenses for this product. - Of the 223 different products imported (excluding different strengths and pack size variations), 67 are held by a single company without competition. - In line with the wider PI industry, the number of licenses granted per quarter has increased steadily over the last 10 years. From an average of 9.75 licenses per quarter in 2013, to 48 per quarter in 2023. Get in touch to discuss a greater breakdown of this, and see PharmaFootpath can provide a competitive advantage for your business.
Australia's English language packs make them a preferred import option for many markets. This month there have been some significant price changes on branded lines... 👇 Most notably, Xolair 75mg/0.5ml saw close to a 50% price reduction, with various Eliquis lines reducing by around 30%. These lines are in high demand, so the new pricing will be attractive to various clients of ours we've alerted!
Hungarian list price information is updated every 6 months, there's been some interesting changes visible from the latest data... 👇 - 31 products have had price changes of +/- 20% or more - The biggest price rise for a single line was 211%! - Of the 9 centrally authorised products, all of these saw price drops, including the popular line for parallel import, Pradaxa - The biggest price drop was seen in a line that is parallel traded by 6 companies, none of which appear to source this in Hungary. A good new opportunity! - One branded product used in over 350 clinical trials globally is now the 2nd cheapest in Europe. Certainly a target for our CTS/comparator sourcing focussed companies! If you'd like more details on any of these points, please get in touch and see how Pharma Footpath data can support
We are delighted to expand our advisory board to include David Browne, who will help provide the company with more pharmaceutical industry experience, particularly in generic and branded pharmaceuticals. Great to have such a wealth of experience join the team!
Most of the work we do at Hawk Pharma Consulting is consultancy projects on marketing strategy, commercial and go-to-market for pharma and healthcare. Delighted to share that David Browne is working with Phil Thomas as a Strategic Board Advisor for Phil's growing business, Pharma Footpath. This is a powerful tool that collates multiple data sources to help many aspects of generic pharma and wholesale trade. Check out the website for some more detail: https://lnkd.in/eZu9maPg